Ferring’s new research with ADSTILADRIN® adds a new feather to clinical practice

Image Credit: Ferring Pharmaceuticals

Announcement 

Ferring Pharmaceuticals confirmed that three abstracts focusing on ADSTILADRIN will be showcased at the 101st Annual Meeting of the Western Section of the American Urological Association (AUA) in Napa, to be held from November 2 to 6, 2025. The CA. ADSTILADRIN is the first and only single intravesical non-replicating gene therapy to receive approval from the US Food and Drug Administration (FDA) for patients suffering from carcinoma in situ (CIS) with or without papillary tumours and high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). New real-world research with its ongoing ADSTILADRIN into the clinical practice may specify or address new concerns or information to improve accuracy and deliver excellent results to both the research and the patient. This will pave new way for development and improvement in clinical practice.

Ferring’s presented study

A ferring’s held study will show the root demographics and characteristics, followed by the primary patient group that participated in ABLE (ADSTILADRIN in bladder cancer)-41. It’s a phase 4 epicentre non-interventional study analysing the use and impact of ADSTILADRIN in a real-world environment. These two self-owned real-world studies will showcase. This involves a study examining electronic billing records for around 101 patients from 19 different US medical centres.

The centers receiving ADSTILADRIN and discovering the timeframe of sticking to ADSTILADRIN and failure of succession to radical cystectomy.  The third abstract will be the case series examining re-induction with ADSTILADRIN in 17 patients covering 8 community and academic settings. The findings for the same were published in the Journal of Urology.

Statements from the healthcare leaders

The MD, director of urologic oncology and Professor of urology and medicine (Oncology) at Keck School of Medicine of the University of Southern California, Sia Daneshmand, said, “The real-world proof delivers an essential viewpoint that ADSTILADRIN can be used in a routine practice and how. The ABLE-4 study will be an integration of this proven dimension by gathering early insights from a vast and diverse patient group than before trials. This will help us to better understand patient experience and detail care for patients with BCG-unresponsive NMIBC.”  

The MD, FRCS(C), Vice President and Global Medical Director-Uro-Oncology at Ferring Pharmaceuticals, Daniel A. Shoskes, said, “ADSTILADRIN is an important alternative for uro-oncologists, providing a convenient and impactful quarterly dosing schedule held administered in the non-chemotherapy and urologist’s office option to radical cystectomy.”